Market Intelligence for Transcription Factor Targeting in Oncology and Genetic Disease
Double Homeobox B (DUXB) is a transcription factor containing two highly conserved homeobox DNA-binding domains. It has emerged as a critical oncogenic driver in fusion-positive sarcomas (via EWSR1-DUXB fusion), an oncofetal factor aberrantly reactivated in hematologic malignancies and solid tumors, and an essential paralog for specificity profiling in Facioscapulohumeral Muscular Dystrophy (FSHD) drug development. These diverse roles create unique assay challenges requiring high-precision biochemical reagents and specialized cell-based validation systems.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DUXB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DUXB Recombinant Protein (Full-Length & Homeodomain Fragments) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 or E. coli expression available. |
View DUXB Products |
| Gene Delivery | DUXB Promise-ORF / Lentivirus Full-length ORF with native NLS for nuclear localization studies. CMV/EF1a promoter options. |
View DUXB Products |
| Benchmark Ab | Anti-DUXB Recombinant Antibody Sequence-verified research-grade positive control for Western blot, IP, and immunofluorescence. |
View DUXB Products |
| Validator | DUXB siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View DUXB Products |
| Fusion Partner | EWSR1 Recombinant Protein Critical for EWSR1-DUXB fusion protein biochemical studies. |
View EWSR1 Products |
| Paralog Control | DUX4 & DUXA Recombinant Proteins Essential for off-target specificity screening and FSHD reference assays. |
View DUX4 Products / View DUXA Products |
| Epigenetic Partner | CREBBP (KAT3A) Protein Transcriptional co-activator interaction studies. |
View CREBBP Products |
| Downstream Marker | ZSCAN4 Recombinant Protein Reporter target for monitoring DUX-family transcriptional activity. |
View ZSCAN4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Nuclear Localization | Full-length ORF with verified NLS sequences; Lentivirus delivery for stable nuclear expression |
| DNA-Binding Domain Folding | Homeobox domain proteins expressed with optimized refolding protocols; High purity (>95%) for crystallography and SPR |
| Paralog Off-Target Binding (DUX4/DUXA/HOX) | High-purity homolog panel proteins (>95%) strictly verified by mass spectrometry for selectivity counter-screening |
| Soluble Expression of Intrinsically Disordered Transcription Factor | HEK293-expressed full-length and truncated variants; endotoxin-controlled; refolded homeodomain options |
| Fusion Protein Biochemistry (EWSR1-DUXB) | Individual EWSR1 (NTD) and DUXB (homeodomain) components available for in vitro fusion reconstruction |
| Lack of Cellular Target Engagement Controls | Lentiviral ORF particles and validated siRNA sets for overexpression and knockdown normalization |
| False Positives in DNA-Binding or Phenotypic Screens | Sequence-verified antigens with theoretical MW confirmation; matched non-binding mutant controls available |
Live DUXB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Sarcoma & DUXB)
- ➤ Latest Resistance Research
- ➤ Latest Transcription Factor Research
- ➤ EWSR1-DUXB Fusion Mechanisms
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
DUXB occupies a strategic position at the intersection of oncology and genetic disease. In oncology, EWSR1-DUXB fusions drive small round cell sarcomas, and DUXB is aberrantly reactivated as an oncofetal transcription factor in acute lymphoblastic leukemia (ALL) and certain refractory solid tumors. In genetic disease, DUXB is the closest paralog of DUX4 (the causative factor in FSHD), making it an indispensable control for DUX4-targeted therapeutics. The field is currently in the preclinical discovery phase, with major research pivoting from traditional "undruggable" transcription factor approaches toward targeted protein degradation (PROTACs, molecular glues), nucleic acid therapeutics (siRNA, ASOs), and small-molecule/peptide homeodomain inhibitors. The next wave of R&D focuses on achieving paralog-selective ligands that disrupt DUXB's DNA-binding or protein-protein interactions while sparing essential physiological transcription factors. Key challenges include ensuring >100-fold selectivity over DUX4/DUXA/HOX proteins and developing fusion-selective degradation strategies for EWSR1-DUXB.
Competitive Modality & Indication Snapshot
| Modality | Representative Approach | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Fusion-selective or paralog-selective degradation | EWSR1-DUXB Sarcoma, ALL, Solid Tumors | Cell-based degradation assays (Need lentivirus for stable DUXB expression; high-purity recombinant proteins for ternary complex formation) |
| Molecular Glue | CRBN-directed DUXB degradation | Solid Tumors, ALL | Ternary complex formation (Need purified DUXB + E3 ligase components; AlphaScreen/TR-FRET) |
| Small Molecule / Peptide Inhibitor | DNA-binding inhibition or PPI blockade | FSHD research, Genetic disease models, Refractory solid tumors | DNA-binding inhibition (Need purified homeodomain proteins >95%; SPR/EMSA assays) |
| RNA-targeting (siRNA/ASO) | Fusion junction or transcript-specific knockdown | Pediatric Sarcoma, FSHD, Oncofetal malignancies | Knockdown validation (Need validated siRNA sets; lentiviral ORF for rescue experiments) |
| PPI Inhibitor | DUXB-CREBBP interaction blockers | Metastatic Disease | AlphaScreen/SPR (Need high-purity recombinant DUXB and CREBBP proteins) |